Latest KFF Health News Stories
Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.
The government soon will stop paying for the covid drug that has proved to be the most effective at keeping patients alive and out of the hospital.
Employers Use Patient Assistance Programs to Offset Their Own Costs
Some insurers and employers are tapping into assistance programs meant for individual patients. The concern: Some costly drugs could be harder for patients to access.
Journalists Discuss Medicaid Rules, Opioid Settlement Funds, and the Public Health Workforce
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.
The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
Watch: The Politics of Health Care in California
KHN senior correspondent Angela Hart discussed the most pressing health care issues in California with the nonpartisan group Democracy Winters in mid-November, touching on a variety of issues, from the state’s effort to transform its Medicaid program to its plan to produce generic insulin.
KHN’s ‘What the Health?’: Medicaid Machinations
The lame-duck Congress has returned to Washington with a long health care to-do list and only a little time. Meanwhile, some of the states that have not yet expanded Medicaid eligibility under the Affordable Care Act are rethinking those decisions. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews KHN’s Fred Clasen-Kelly, who reported and wrote the latest KHN-NPR “Bill of the Month” feature, about a mysterious mishap during minor surgery.
Readers and Tweeters Decry Medical Billing Errors, Price-Gouging, and Barriers to Benefits
KHN gives readers a chance to comment on a recent batch of stories.
Schools, Sheriffs, and Syringes: State Plans Vary for Spending $26B in Opioid Settlement Funds
The cash represents an unprecedented opportunity to derail the opioid epidemic, but with countless groups advocating for their share of the pie, the impact could depend heavily on geography and politics.
Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets
Many of the pharmacies were small, independent operations that had decided not to participate next year because of the lowered reimbursement being offered. But they were surprised by an early dismissal, and some patients with specialized drug needs could face difficulties in the transition.
Pfizer’s Covid Cash Powers a ‘Marketing Machine’ on the Hunt for New Supernovas
While sales of its covid vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.
Readers and Tweeters Take Positions on Sleep Apnea Treatment
KHN gives readers a chance to comment on a recent batch of stories.
$38,398 for a Single Shot of a Very Old Cancer Drug
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?
KHN’s ‘What the Health?’: Biden Hits the Road to Sell Democrats’ Record
With the midterm elections rapidly approaching, President Joe Biden has taken to the road to convince voters that he and congressional Democrats have delivered for them during two years in power. Among the health issues highlighted by the administration this week are pandemic preparedness and the availability of over-the-counter hearing aids. The president also promised to sign a bill codifying the abortion protections of Roe v. Wade if Democrats maintain control of the House and Senate — even though it’s a long shot that there will be enough votes for that. Sarah Karlin-Smith of the Pink Sheet, Sandhya Raman of CQ Roll Call, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
El vínculo con la esclerosis múltiple impulsa una vacuna contra el virus Epstein-Barr
Los científicos llevan años intentando desarrollar vacunas contra este virus. Sin embargo, recientemente varios avances en la investigación médica han dado más urgencia a la búsqueda y más esperanzas de éxito.
As Links to MS Deepen, Researchers Accelerate Efforts to Develop an Epstein-Barr Vaccine
Recent leaps in medical research have lent urgency to the quest to develop a vaccine against Epstein-Barr, a ubiquitous virus that has been linked to a range of illnesses, from mononucleosis to multiple sclerosis and several cancers.
La nueva generación de medicamentos para la pérdida de peso es prometedora, pero tiene un precio
Algunos pacientes, según los especialistas en medicina de la obesidad, experimentan una disminución de la presión arterial, un mejor control de la diabetes, menos dolor en las articulaciones y un mejor sueño gracias a estos nuevos tratamientos.
New Generation of Weight Loss Medications Offer Promise — But at a Price
People now have at their disposal more medicines that are effective at reducing weight, but none can counter obesity alone. One big problem: Insurance coverage remains spotty, and the costly drugs may be needed long term.
Severe Sleep Apnea Diagnosis Panics Reporter Until He Finds a Simple, No-Cost Solution
An industry has grown up around sleep apnea, stirring concerns about overdiagnosis and overtreatment.
Pharma-Funded FDA Gets Drugs Out Faster, But Some Work Only ‘Marginally’ and Most Are Pricey
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.
